Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.43
0.020.45%
At close: -
$4.43
0.000.00%
After Hours: 7:52 PM EDT
Comments
Loading...
Medical Properties Trust Analyst Ratings and Price Targets | NYSE:MPW | Benzinga
Medical Properties Trust Inc has a consensus price target of $9.33 based on the ratings of 20 analysts. The high is $18 issued by Keybanc on July 7, 2022. The low is $4 issued by Truist Securities on December 19, 2024. The 3 most-recent analyst ratings were released by Exane BNP Paribas, RBC Capital, and Wells Fargo on March 12, 2025, March 10, 2025, and March 10, 2025, respectively. With an average price target of $6.33 between Exane BNP Paribas, RBC Capital, and Wells Fargo, there's an implied 42.96% upside for Medical Properties Trust Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Exane BNP Paribas
RBC Capital
Wells Fargo
Truist Securities
Mizuho
1calculated from analyst ratings
Analyst Ratings for Medical Properties Trust
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | Buy Now | 103.16% | Exane BNP Paribas | Nate Crossett50% | $5 → $9 | Upgrade | Neutral → Outperform | Get Alert |
| 03/10/2025 | Buy Now | 12.87% | RBC Capital | Michael Carroll62% | $4 → $5 | Maintains | Sector Perform | Get Alert |
| 03/10/2025 | Buy Now | 12.87% | Wells Fargo | Connor Siversky68% | $4 → $5 | Maintains | Underweight | Get Alert |
| 12/19/2024 | Buy Now | -9.71% | Truist Securities | Michael Lewis69% | $6 → $4 | Maintains | Hold | Get Alert |
| 12/05/2024 | Buy Now | 12.87% | Mizuho | Vikram Malhotra56% | $6 → $5 | Maintains | Neutral | Get Alert |
| 09/13/2024 | Buy Now | 35.44% | Truist Securities | Michael Lewis69% | $5 → $6 | Maintains | Hold | Get Alert |
| 09/13/2024 | Buy Now | 46.73% | Colliers Securities | David Toti39% | → $6.5 | Upgrade | Neutral → Buy | Get Alert |
| 07/02/2024 | Buy Now | -9.71% | Exane BNP Paribas | Nate Crossett50% | $6 → $4 | Downgrade | Outperform → Neutral | Get Alert |
| 05/30/2024 | Buy Now | 12.87% | Truist Securities | Michael Lewis69% | $4.5 → $5 | Maintains | Hold | Get Alert |
| 05/14/2024 | Buy Now | 12.87% | RBC Capital | Michael Carroll62% | → $5 | Downgrade | Outperform → Sector Perform | Get Alert |
| 04/17/2024 | Buy Now | 12.87% | Deutsche Bank | Omotayo Okusanya63% | $2 → $5 | Upgrade | Sell → Hold | Get Alert |
| 04/15/2024 | Buy Now | 12.87% | Colliers Securities | David Toti39% | $4.25 → $5 | Maintains | Neutral | Get Alert |
| 04/08/2024 | Buy Now | 1.58% | Truist Securities | Michael Lewis69% | $4 → $4.5 | Maintains | Hold | Get Alert |
| 03/01/2024 | Buy Now | 35.44% | Exane BNP Paribas | Nate Crossett50% | → $6 | Upgrade | Neutral → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 12.87% | RBC Capital | Michael Carroll62% | $8 → $5 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | -54.85% | Deutsche Bank | Omotayo Okusanya63% | → $2 | Initiates | → Sell | Get Alert |
| 01/05/2024 | Buy Now | — | Keybanc | Austin Wurschmidt57% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 01/03/2024 | Buy Now | 58.01% | Mizuho | Vikram Malhotra56% | $9 → $7 | Maintains | Neutral | Get Alert |
| 11/29/2023 | Buy Now | 12.87% | JP Morgan | Michael Lapides60% | $8 → $5 | Maintains | Underweight | Get Alert |
| 11/10/2023 | Buy Now | 1.58% | Stifel | Stephen Manaker44% | $12 → $4.5 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | Buy Now | -9.71% | Wells Fargo | Connor Siversky68% | $7 → $4 | Maintains | Underweight | Get Alert |
| 10/16/2023 | Buy Now | -9.71% | Wells Fargo | Connor Siversky68% | → $4 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 09/25/2023 | Buy Now | 125.73% | RBC Capital | Michael Carroll62% | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | Buy Now | 103.16% | Mizuho | Vikram Malhotra56% | $18 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 08/22/2023 | Buy Now | 125.73% | Barclays | Steve Valiquette52% | $12 → $10 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 58.01% | JP Morgan | Michael Lapides60% | $9 → $7 | Downgrade | Neutral → Underweight | Get Alert |
| 08/14/2023 | Buy Now | 125.73% | RBC Capital | Michael Carroll62% | $12 → $10 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 80.59% | B of A Securities | Joshua Dennerlein49% | $9 → $8 | Downgrade | Neutral → Underperform | Get Alert |
| 08/11/2023 | Buy Now | — | Raymond James | Jonathan Hughes65% | — | Downgrade | Strong Buy → Underperform | Get Alert |
| 06/23/2023 | Buy Now | 125.73% | Truist Securities | Michael Lapides60% | $9 → $10 | Maintains | Hold | Get Alert |
| 04/20/2023 | Buy Now | 103.16% | Wells Fargo | Connor Siversky68% | → $9 | Initiates | → Equal-Weight | Get Alert |
| 04/19/2023 | Buy Now | 103.16% | Wells Fargo | Connor Siversky68% | → $9 | Initiates | → Equal-Weight | Get Alert |
| 04/05/2023 | Buy Now | 170.88% | Barclays | Steve Valiquette52% | $14 → $12 | Maintains | Overweight | Get Alert |
| 04/04/2023 | Buy Now | 238.6% | Keybanc | Austin Wurschmidt57% | $16 → $15 | Maintains | Overweight | Get Alert |
| 03/31/2023 | Buy Now | 103.16% | Truist Securities | Michael Lapides60% | $8 → $9 | Maintains | Hold | Get Alert |
| 03/29/2023 | Buy Now | 80.59% | Truist Securities | Michael Lewis69% | $14 → $8 | Maintains | Hold | Get Alert |
| 03/16/2023 | Buy Now | 125.73% | B of A Securities | Joshua Dennerlein49% | → $10 | Downgrade | Buy → Neutral | Get Alert |
| 03/07/2023 | Buy Now | 148.31% | Credit Suisse | Omotayo Okusanya63% | → $11 | Reiterates | → Neutral | Get Alert |
| 03/03/2023 | Buy Now | 170.88% | JP Morgan | Michael Lapides60% | $14 → $12 | Maintains | Neutral | Get Alert |
| 03/02/2023 | Buy Now | 261.17% | Raymond James | Jonathan Hughes65% | $18 → $16 | Maintains | Strong Buy | Get Alert |
| 02/27/2023 | Buy Now | 216.03% | Barclays | Steven Valiquette58% | $17 → $14 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 148.31% | Credit Suisse | Omotayo Okusanya63% | $13 → $11 | Maintains | Neutral | Get Alert |
| 01/27/2023 | Buy Now | 283.75% | Barclays | Steve Valiquette52% | $19 → $17 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | 261.17% | Keybanc | Austin Wurschmidt57% | $18 → $16 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 193.45% | Credit Suisse | Omotayo Okusanya63% | $11 → $13 | Maintains | Neutral | Get Alert |
| 12/21/2022 | Buy Now | 148.31% | Credit Suisse | Omotayo Okusanya63% | $17 → $11 | Maintains | Neutral | Get Alert |
| 11/14/2022 | Buy Now | 261.17% | B of A Securities | Joshua Dennerlein49% | → $16 | Upgrade | Neutral → Buy | Get Alert |
| 10/21/2022 | Buy Now | 328.89% | Barclays | Steve Valiquette52% | $23 → $19 | Maintains | Overweight | Get Alert |
| 10/04/2022 | Buy Now | 306.32% | RBC Capital | Michael Carroll62% | $20 → $18 | Maintains | Outperform | Get Alert |
| 09/22/2022 | Buy Now | 306.32% | Raymond James | Jonathan Hughes65% | $20 → $18 | Maintains | Strong Buy | Get Alert |
| 09/16/2022 | Buy Now | 238.6% | Deutsche Bank | Derek Johnston52% | $17 → $15 | Maintains | Hold | Get Alert |
| 08/04/2022 | Buy Now | 419.19% | Barclays | Steve Valiquette52% | $27 → $23 | Maintains | Overweight | Get Alert |
| 07/29/2022 | Buy Now | 351.47% | Mizuho | Vikram Malhotra56% | $26 → $20 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 351.47% | Raymond James | Jonathan Hughes65% | $24 → $20 | Maintains | Strong Buy | Get Alert |
| 07/14/2022 | Buy Now | 283.75% | Credit Suisse | Omotayo Okusanya63% | $23 → $17 | Downgrade | Outperform → Neutral | Get Alert |
| 07/13/2022 | Buy Now | 283.75% | Deutsche Bank | Derek Johnston52% | $20 → $17 | Maintains | Hold | Get Alert |
| 07/07/2022 | Buy Now | 306.32% | Keybanc | Josh Beck77% | $23 → $18 | Maintains | Overweight | Get Alert |
| 06/30/2022 | Buy Now | 238.6% | Jefferies | Jonathan Petersen60% | $19 → $15 | Maintains | Hold | Get Alert |
| 06/22/2022 | Buy Now | 306.32% | JP Morgan | Michael Mueller54% | $24 → $18 | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for Medical Properties Trust (MPW) stock?
The latest price target for Medical Properties Trust (NYSE:MPW) was reported by Exane BNP Paribas on March 12, 2025. The analyst firm set a price target for $9.00 expecting MPW to rise to within 12 months (a possible 103.16% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medical Properties Trust (MPW)?
The latest analyst rating for Medical Properties Trust (NYSE:MPW) was provided by Exane BNP Paribas, and Medical Properties Trust upgraded their outperform rating.
When was the last upgrade for Medical Properties Trust (MPW)?
The last upgrade for Medical Properties Trust Inc happened on March 12, 2025 when Exane BNP Paribas raised their price target to $9. Exane BNP Paribas previously had a neutral for Medical Properties Trust Inc.
When was the last downgrade for Medical Properties Trust (MPW)?
The last downgrade for Medical Properties Trust Inc happened on July 2, 2024 when Exane BNP Paribas changed their price target from $6 to $4 for Medical Properties Trust Inc.
When is the next analyst rating going to be posted or updated for Medical Properties Trust (MPW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
Is the Analyst Rating Medical Properties Trust (MPW) correct?
While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a upgraded with a price target of $5.00 to $9.00. The current price Medical Properties Trust (MPW) is trading at is $4.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
